CN103983763A - Reactivity of colon cancer artery to vasoconstrictive medium - Google Patents
Reactivity of colon cancer artery to vasoconstrictive medium Download PDFInfo
- Publication number
- CN103983763A CN103983763A CN201410206440.2A CN201410206440A CN103983763A CN 103983763 A CN103983763 A CN 103983763A CN 201410206440 A CN201410206440 A CN 201410206440A CN 103983763 A CN103983763 A CN 103983763A
- Authority
- CN
- China
- Prior art keywords
- artery
- cancer
- contraction
- acceptor
- colon cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001367 artery Anatomy 0.000 title claims abstract description 143
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 36
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 28
- 230000009257 reactivity Effects 0.000 title claims abstract description 14
- 230000003639 vasoconstrictive effect Effects 0.000 title abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 110
- 201000011510 cancer Diseases 0.000 claims abstract description 98
- 210000004204 blood vessel Anatomy 0.000 claims description 18
- 230000008602 contraction Effects 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 17
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract description 8
- 229960002748 norepinephrine Drugs 0.000 abstract description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract description 7
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 239000005526 vasoconstrictor agent Substances 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 33
- 102100033902 Endothelin-1 Human genes 0.000 description 19
- 101800004490 Endothelin-1 Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000009989 contractile response Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000002550 vasoactive agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- LXPHPKVWHQLBBA-JHOSIGDNSA-N chembl2165327 Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@@H](C)O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 LXPHPKVWHQLBBA-JHOSIGDNSA-N 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004249 mesenteric artery inferior Anatomy 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- -1 NA) Chemical compound 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410206440.2A CN103983763A (en) | 2014-05-16 | 2014-05-16 | Reactivity of colon cancer artery to vasoconstrictive medium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410206440.2A CN103983763A (en) | 2014-05-16 | 2014-05-16 | Reactivity of colon cancer artery to vasoconstrictive medium |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103983763A true CN103983763A (en) | 2014-08-13 |
Family
ID=51275815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410206440.2A Pending CN103983763A (en) | 2014-05-16 | 2014-05-16 | Reactivity of colon cancer artery to vasoconstrictive medium |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103983763A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070065866A1 (en) * | 2002-12-23 | 2007-03-22 | William Marsh Rice University | Compositions and Methods for Suppressing Fibrocytes |
-
2014
- 2014-05-16 CN CN201410206440.2A patent/CN103983763A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070065866A1 (en) * | 2002-12-23 | 2007-03-22 | William Marsh Rice University | Compositions and Methods for Suppressing Fibrocytes |
Non-Patent Citations (1)
Title |
---|
祁光裕等: "结肠癌血管的肾上腺素受体和内皮素受体", 《西安交通大学学报》, vol. 27, no. 4, 31 August 2006 (2006-08-31) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Long noncoding RNA NEAT1 promotes proliferation and invasion via targeting miR-181a-5p in non-small cell lung cancer | |
Zarour et al. | Colorectal cancer liver metastasis: evolving paradigms and future directions | |
Andonegui-Elguera et al. | An overview of vasculogenic mimicry in breast cancer | |
Fung et al. | Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma | |
Yang et al. | Downregulation of PDK4 increases lipogenesis and associates with poor prognosis in hepatocellular carcinoma | |
Luo et al. | Circ-ITCH correlates with small tumor size, decreased FIGO stage and prolonged overall survival, and it inhibits cells proliferation while promotes cells apoptosis in epithelial ovarian cancer | |
Piao et al. | LETM1 is a potential cancer stem-like cell marker and predicts poor prognosis in colorectal adenocarcinoma | |
Zhan et al. | Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas | |
Luo et al. | CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma | |
Liu et al. | Identification of a three-RNA binding proteins (RBPs) signature predicting prognosis for breast cancer | |
Acun et al. | HLJ1 (DNAJB4) gene is a novel biomarker candidate in breast cancer | |
Tan et al. | Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma | |
Sharma et al. | Histomorphological spectrum of prostatic lesions: a retrospective analysis of transurethral resection of prostate specimens | |
Yoshida et al. | Immunohistochemical detection of cervical lymph node micrometastases from T2N0 tongue cancer | |
Yang et al. | Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma | |
Heng et al. | A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker | |
Shi et al. | Up-regulation of T-lymphoma and metastasis gene 1 in gastric cancer and its involvement in cell invasion and migration | |
Jiang et al. | Role of tumor-derived exosomes in metastasis, drug resistance and diagnosis of clear cell renal cell carcinoma | |
Wang et al. | Expression of long noncoding RNA NBAT1 is associated with the outcome of patients with non-small cell lung cancer | |
CN103983763A (en) | Reactivity of colon cancer artery to vasoconstrictive medium | |
Ahmadi et al. | Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma | |
Han et al. | Expression of TRAP1 in gastric cancer tissue and its correlation with malignant biology | |
Aiad et al. | The prognostic and predictive significance of PARP-1 in locally advanced breast cancer of Egyptian patients receiving neoadjuvant chemotherapy | |
Sha et al. | Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study | |
Lu et al. | The clinical relevance and tumor promoting function of C19orf10 in kidney renal clear cell carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LIN JIE WANG JUNJIE Effective date: 20150225 Owner name: CHENZHOU FIRST PEOPLE S HOSPITAL Free format text: FORMER OWNER: LI JIE Effective date: 20150225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150225 Address after: Luo Jia Jing 423000 Chenzhou province Hunan City Beihu District No. 102 Applicant after: Chenzhou First People's Hospital Address before: Luo Jia Jing 423000 Chenzhou province Hunan City Beihu District No. 102 Applicant before: Li Jie Applicant before: Lin Jie Applicant before: Wang Junjie |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140813 |